Srinivas Akkaraju
Sits on 5 boards. Overboarded · 5 public boards Last updated September 27, 2026
Time on boards
- Boards served
- 5
- Current seats
- 5
- Board service
- 13 years
- Director since
- 2023
13 years of board service in total across 5 boards, counting each seat separately. Longest: Mineralys Therapeutics Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Mineralys Therapeutics Inc. May 21, 202660.6%
-
Kalaris Therapeutics Inc. August 12, 202599.0%
-
Alumis Inc. July 30, 202587.7%
-
vTv Therapeutics Inc. June 10, 202594.7%
-
vTv Therapeutics Inc. June 11, 202499.6%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 8, 2026 | Alumis Inc. | Open-market sale | −48,066 | $10.55 | $507,019 |
| Sep 8, 2026 | Alumis Inc. | Open-market sale | −48,065 | $10.55 | $507,009 |
| Sep 8, 2026 | Alumis Inc. | Open-market purchase | +273,291 | $10.63 | $2,904,291 |
| Sep 8, 2026 | Alumis Inc. | Open-market purchase | +273,290 | $10.63 | $2,904,280 |
| Sep 4, 2026 | Alumis Inc. | Open-market purchase | +220,070 | $11.17 | $2,458,842 |
| Sep 4, 2026 | Alumis Inc. | Open-market purchase | +220,070 | $11.17 | $2,458,842 |
| Jun 30, 2026 | Alumis Inc. | Grant or award | +3,553 | — | — |
| Jun 4, 2026 | Scholar Rock Holding Corporation | Grant or award | +6,839 | — | — |
| May 20, 2026 | Kalaris Therapeutics Inc. | Open-market purchase | +244,300 | $4.83 | $1,179,969 |
| May 20, 2026 | Kalaris Therapeutics Inc. | Other | −66,906 | — | — |
| May 20, 2026 | Kalaris Therapeutics Inc. | Other | +14,937 | — | — |
| May 20, 2026 | Kalaris Therapeutics Inc. | Other | +4,471 | — | — |
| Feb 19, 2026 | Mineralys Therapeutics Inc. | Grant or award | +6,200 | — | — |
| Jan 9, 2026 | Alumis Inc. | Open-market purchase | +588,235 | $17.00 | $9,999,995 |
| Dec 22, 2025 | Kalaris Therapeutics Inc. | Grant or award | +1,500,000 | $10.00 | $15,000,000 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.